e-SPACE Cardio-Renal-Metabolic 2022: On-demand
Published: 11 April 2022
-
Views:
20256
-
Likes:
7
-
Views:
20256
-
Likes:
7
-
Up Next -
24m 22sPart 22 | Session 6 Panel discussion
-
50sPart 24 | Session 1 Introduction
-
8m 22sPart 24 | Session 2 Practical issues of managing weight loss in CRM disease: the therapeutic options
-
8m 9sPart 24 | Session 3 Managing weight loss in CRM disease: the nephrologist's perspective
-
8m 31sPart 24 | Session 4 Managing weight loss in CRM disease: the diabetologist's perspective
-
8m 33sPart 24 | Session 5 Managing weight loss in CRM disease: the cardiologists' perspective
-
25m 47sPart 24 | Session 6 Panel discussion
-
1m 30sPart 25 | Session 1 Welcome and introduction
-
16m 6s
-
16m 1sPart 25 | Session 3 Interactive panel discussion
-
31m 2s
-
2m 39sPart 27 | Session 1 Introduction
-
6m 32sPart 27 | Session 2 DAPA CKD: Key lessons from subgroup analyses
-
6m 41sPart 27 | Session 3 FIDELIO/FIGARO DKD
-
8m 34sPart 27 | Session 4 FIDELITY - Main lessons including subgroup analyses
-
11m 1sPart 27 | Session 5 Chlortalidone in CKD stage 4: A new look at an old drug
-
25m 1sPart 27 | Session 6 Panel discussion
-
2m 1sPart 28 | Session 1 Introduction
-
4m 33sPart 28 | Session 2 Screening and diagnosis best practices
-
5m 48sPart 28 | Session 3 Primary care perspective and challenges
-
10m 3sPart 28 | Session 4 Reducing CV risks and new treatment options: case discussion
-
17m 19sPart 28 | Session 5 Panel discussion
-
1m 23sPart 29 | Session 1 Introduction
-
8m 38sPart 29 | Session 2 Digital technologies in CV disease
-
7m 39sPart 29 | Session 3 Remote monitoring of HF
-
34m 11sPart 29 | Session 4 Panel discussion
-
5m 21sPart 30 | Session 1 Introduction
-
8m 24sPart 30 | Session 2 Ascend D and ASCEND ND
-
7m 42sPart 30 | Session 3 The moving field of drug nephrotoxicity
-
8m 22sPart 30 | Session 4 The role of new potassium binding agents in cardio-renal medicine
-
31m 33sPart 30 | Session 5 Panel discussion
-
32m 21s
-
1m 50sPart 32 | Session 1 Introduction
-
6m 50sPart 32 | Session 2 Cardio-centric approach
-
9m 15sPart 32 | Session 3 Gluco-centric approach
-
15m 19sPart 32 | Session 4 Combination therapy as starting option
-
27m 15sPart 32 | Session 5 Panel discussion
-
31m 10sPart 1 Meet the Expert: IgA nephropathy: current optimal management Sydney Tang
-
55sPart 2 | Session 1 Welcome and introduction
-
9m 28sPart 2 | Session 2 1.1: BP in CKD Guidelines
-
8m 48sPart 2 | Session 3 1.2: Diabetes and CKD GL
-
7m 30sPart 2 | Session 4 1.3: General management of the nephrotic syndrome
-
31m 57sPart 2 | Session 5 Panel Discussion
-
1m 4sPart 3 | Session 1 Welcome and Introduction Ewa Jankowska
-
8m 2sPart 3 | Session 2 Management of iron deficiency in heart failure: new evidence, new guidelines
-
10m 31sPart 3 | Session 3 Iron deficiency in chronic kidney disease: why iron matters beyond anaemia
-
11m 28sPart 3 | Session 4 Interactive panel discussion
-
1m 29sPart 4 | Session 1 Introduction Vijay Chopra, Marco Metra
-
16m 37sPart 4 | Session 2 2.1: The new ESC HF guidelines
-
8m 23sPart 4 | Session 3 2.2: Personalised management
-
9m 7sPart 4 | Session 4 2.3: Preventive cardiology
-
25m 36sPart 4 | Session 5 Panel Discussion
-
1m 9sPart 6 | Session 1 Introduction Andrew JS Coats, Alice Cheng
-
8m 4sPart 6 | Session 2 3.1: Focus on diabetology Andrew JS Coats, Alice Cheng
-
9m 10sPart 6 | Session 3 3.2: Focus on cardiology Andrew JS Coats, Alice Cheng
-
7m 30sPart 6 | Session 4 3.3: Focus on nephrology Andrew JS Coats, Alice Cheng
-
33m 58sPart 6 | Session 5 Panel Discussion Andrew JS Coats, Alice Cheng
-
1m 13sPart 7 | Session 1 Introduction Roland E Schmieder
-
7m 28sPart 7 | Session 2 The meaning of Hemoglobin A1C for the nephrologist Roland E Schmieder
-
8m 10sPart 7 | Session 3 The meaning of Hemoglobin A1C for the cardiologist Roland E Schmieder
-
14m 13sPart 7 | Session 4 Panel discussion Roland E Schmieder
-
2m 6sPart 8 | Session 1 Introduction
-
8m 15sPart 8 | Session 2 4.1: GLP-1RA and CVD in diabetes
-
8m 15sPart 8 | Session 3 4.2: GLP-1 RA and kidney disease in diabetes
-
6m 6sPart 8 | Session 4 4.3: Obesity and cardio-metabolic disease: Role of GLP-1RA
-
1m 6sPart 9 | Session 1 Welcome and introduction Andrew JS Coats
-
5m 20sPart 9 | Session 2 Cardio-renal-metabolic disease in a nutshell Andrew JS Coats
-
6m 45sPart 9 | Session 3 SGLT2 inhibitors in patients with type 2 diabetes and comorbidities Andrew JS Coats
-
6m 42sPart 9 | Session 4 SGLT2 inhibitors in patients with heart failure and comorbidities Andrew JS Coats
-
5m 2sPart 9 | Session 5 SGLT2 inhibitors in patients with chronic kidney disease and comorbidities Andrew JS Coats
-
13m 56sPart 9 | Session 6 Panel discussion Andrew JS Coats
-
1m 39sPart 10 | Session 1 Introduction
-
8m 59sPart 10 | Session 2 5.1: Diagnosis, pathophysiology, epidemiology
-
10mPart 10 | Session 3 5.2: Diabetes
-
8m 6sPart 10 | Session 4 5.3: In chronic kidney disease
-
7m 3s
-
25m 14sPart 10 | Session 6 Panel discussion
-
1mPart 11 | Session 1 Introduction Mustafa Arici, Pardeep Jhund
-
7m 24sPart 11 | Session 2 Mechanism of disease interplay between CVD and CKD Mustafa Arici, Pardeep Jhund
-
9m 6sPart 11 | Session 3 The use of SGLT2is in patients with CKD and CVD with and without diabetes Mustafa Arici, Pardeep Jhund
-
13m 6sPart 11 | Session 4 Panel discussion Mustafa Arici, Pardeep Jhund
-
28m 54s
-
1m 15sPart 13 | Session 1 Introduction Fausto J Pinto, Clara Saldarriaga, Stefan Anker
-
8m 21sPart 13 | Session 2 6.1: EMPEROR-Preserved Fausto J Pinto, Clara Saldarriaga, Stefan Anker
-
8m 55sPart 13 | Session 3 6.2: Preserved HF Fausto J Pinto, Clara Saldarriaga, Stefan Anker
-
7m 33sPart 13 | Session 4 6.3: Dronedarone in AF management: A 2022 update Fausto J Pinto, Clara Saldarriaga, Stefan Anker
-
10m 41sPart 13 | Session 5 6.4: Upcoming trials in 2022 (Deliver, Diamond, Iron Man) Fausto J Pinto, Clara Saldarriaga, Stefan Anker
-
24m 16sPart 13 | Session 6 Panel discussion Fausto J Pinto, Clara Saldarriaga, Stefan Anker
-
36m 25sPart 14 Meet the Experts: The HF Diabetic patient with CKD: optimizing care for a high-risk group Silvio Inzucchi, Milton Packer
-
52sPart 15 | Session 1 Introduction Javed Butler
-
5m 46sPart 15 | Session 2 The case for early identification, risk stratification and treatment of CKD Javed Butler
-
5m 24sPart 15 | Session 3 Protecting the kidney and the heart: the cardiologist's perspective Javed Butler
-
6m 52sPart 15 | Session 4 Identifying high-risk patients: the primary care physician's perspective Javed Butler
-
11m 16sPart 15 | Session 5 Panel discussion Javed Butler
-
57sPart 16 | Session 1 Welcome and introduction Stefan Anker, Stephan Von Haehling
-
8m 59sPart 16 | Session 2 8.1: Cachexia in CV disease Stefan Anker, Stephan Von Haehling
-
8m 30sPart 16 | Session 3 8.2: Cachexia in CKD Stefan Anker, Stephan Von Haehling
-
8m 37sPart 16 | Session 4 8.3: Muscle wasting in stroke Stefan Anker, Stephan Von Haehling
-
31m 48sPart 16 | Session 5 Panel discussion Stefan Anker, Stephan Von Haehling
-
28m 46sPart 17 Meet the Expert: HIF PHI: What do we know and don't know in 2022 David Wheeler
-
1m 44sPart 18 | Session 1 Introduction Giuseppe Rosano
-
7m 46sPart 18 | Session 2 9.1: Diabetes and CVD today Giuseppe Rosano
-
3m 53sPart 18 | Session 3 9.2: Diabetes and kidney today Giuseppe Rosano
-
7m 30sPart 18 | Session 4 9.3: The cross-talk between kidney and heart Giuseppe Rosano
-
7m 23sPart 18 | Session 5 9.4: Therapeutic solution Giuseppe Rosano
-
24m 37sPart 18 | Session 6 Panel discussion Giuseppe Rosano
-
30m 11sPart 19 | Session 1 SGLT2 inhibition in the comorbid CKD patient Muthiah Vaduganathan
-
4m 26sPart 19 | Session 2 Panel discussion Muthiah Vaduganathan
-
2m 10sPart 20 | Session 1 Introduction
-
8m 29sPart 20 | Session 2 10.1: Screening of kidney disease
-
8m 11sPart 20 | Session 3 10.2: Screening of heart failure
-
8m 15sPart 20 | Session 4 10.3: Horizons opened by the screening
-
33m 48sPart 20 | Session 5 Panel discussion
-
1m 14sPart 21 | Session 1 Welcome and introduction Shelley Zieroth, Giuseppe Rosano
-
9m 27sPart 21 | Session 2 New developments in SGLT2 inhibitor use in HFrEF and HFpEF Shelley Zieroth, Giuseppe Rosano
-
9m 15sPart 21 | Session 3 Implementing guidelines in clinical practice Shelley Zieroth, Giuseppe Rosano
-
10m 43sPart 21 | Session 4 Panel discussion Shelley Zieroth, Giuseppe Rosano
-
2m 7sPart 22 | Session 1 Introduction Piotr Ponikowski, Muthiah Vaduganathan
-
8m 22sPart 22 | Session 2 In ambulatory HFrEF and HFpEF Piotr Ponikowski, Muthiah Vaduganathan
-
8m 22sPart 22 | Session 3 When to start after acute decompensation Piotr Ponikowski, Muthiah Vaduganathan
-
9m 38sPart 22 | Session 4 Improving QoL and symptoms Piotr Ponikowski, Muthiah Vaduganathan
Overview
e-SPACE CARDIO-RENAL-METABOLIC 2022, held on 4-6 March 2022, was the second edition of the global online conference on cardio renal metabolic diseases.
The organisers, under the direction of a world-renowned scientific committee, brought together leading experts in cardiology, nephrology, and diabetology to share clinical practice strategies in treating the inter-related diseases now affecting hundreds of millions people worldwide.
This on-demand version of the event comprises:
- Presentations and discussions with leading experts
- Evidence-based management strategies for diabetes, cardiovascular disease, heart failure, kidney disease & obesity
- Insight to SLGT2i, GLP-1RA and other emerging therapies
- 'Meet the Expert' sessions
e-SPACE Cardio-Renal-Metabolic 2022 was supported by the following companies:
More from this programme
Part 1
Meet the Expert: IgA nephropathy: current optimal management
Part 2
Session 1: The new KDIGO guidelines
Part 3
Industry Session: Iron deficiency in heart failure and kidney disease: interdisciplinary crosstalk
Supported by an unrestricted educational grant from Vifor Pharma
Part 4
Session 2: Recent CV guidelines and treatment algorithms
Part 5
Meet the Experts: NAFLD/NASH as a metabolic disease: improving patients outcomes
Part 6
Session 3: Management of SGLT2 a practical approach
Part 7
Meet the Experts: The meaning of Hemoglobin A1C for the nephrologist and the cardiologist
Part 8
Session 4: GLP-1RA and cardio-metabolic disease in diabetes
Part 9
Industry Session: SGLT2 inhibitors in cardio-renal-metabolic disease: optimizing the patient's journey
Supported by an independent educational grant from Boehringer Ingelheim & Eli Lilly Alliance
Part 10
Session 5: HFpEF: tackling a multidisciplinary problem
Part 11
Meet the Experts: CKD progression in CVD screening and follow-up
Part 12
Meet the Experts: CV, mortality & kidney outcomes with GLP-1 AR in patients with T2DM
Part 13
Session 6: New trial update in cardiology
Part 14
Meet the Experts: The HF Diabetic patient with CKD: optimizing care for a high-risk group
Part 15
Meet the Expert: Multidisciplinary management of cardio-renal-metabolic disease: focus on the kidney
Part 16
Session 8: Sarcopenia, frailty malnutrition and cachexia
Part 17
Meet the Expert: HIF PHI: What do we know and don't know in 2022
Part 18
Session 9: The cardio-kidney interaction: relevance to diabetes
Part 19
Industry Session: SGLT2 inhibition in the comorbid CKD patient
Satellite Symposium supported by an unrestricted educational grant from AstraZeneca
Part 20
Session 10: Why and how to screen for heart failure and kidney disease in diabetes
Part 21
Meet the Expert: SGLT2 inhibitors in heart failure: Improving outcomes across the spectrum of the disease
Part 22
Session 11: SGLT2 inhibition in clinical practice
Part 23
Meet the Expert: The meaning of eGFR for the cardiologists and diabetologist
Part 24
Session 12: Managing obesity in the CRM setting
Part 25
Meet the Experts: Personalized care of patients with heart failure: hyperkalemia as a barrier to optimal medical therapy
Part 26
Meet the Expert: SGLT2, the statin of the 21st century
Part 27
Session 13: New trial update in nephrology
Part 28
Meet the Experts: Reducing the risk of cardiovascular events for patients with CKD and T2DM: new treatment options
Part 29
Session 14: Telemedicine in CRM
Part 30
Session 15: New drugs, new hopes and sometimes risks
Part 31
Meet the Expert: Management of worsening HF
Part 32
Session 16: Harmonising the gluco-and cardio-centric management of diabetes
Faculty Biographies
Piotr Ponikowski
Head of the Department of Heart Diseases
Piotr Ponikowski is Head of the Department of Heart Diseases, Wroclaw Medical University and Head of the Cardiology Department at the Center for Heart Diseases at 4th Military Hospital, Wroclaw, Poland. His research interests mainly include heart failure (HF), coronary artery disease and cardiac arrhythmias. He has been involved in numerous research projects, such as the benefits of physical rehabilitation in patients with chronic HF, assessment of metabolic derangements in HF (with special interest in iron deficiency), evaluation of reflex control in the cardiorespiratory system in order to optimise assessment and management of patients with HF. He has been involved in numerous clinical trials as main investigator, member of international steering committees, endpoint committees and advisory boards.
Muthiah Vaduganathan
Co-Director, Center for Cardiometabolic Implementation Science
Dr Muthiah Vaduganathan is a Cardiologist and Clinical Trialist at Brigham and Women’s Hospital and Harvard Medical School, Boston, US. He is co-director of the Center for Cardiometabolic Implementation Science at Brigham and Women’s Hospital. He serves as an Associate Editor of JACC and as US national ambassador to the ESC Heart Failure Association. His research focuses on drug development, clinical trials, and implementation of cardio-kidney-metabolic therapies, and he has authored or co-authored more than 700 peer-reviewed publications. He participates on study leadership of ongoing advanced-phase trials in cardio-kidney-metabolism and heart failure.